Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

Millions of Americans are born predisposed to high levels of a cholesterol called lipoprotein(a). Doctors are finally figuring out how to treat it.